RxDoctor Payments Data

Allarice Linaac, MD

Internal Medicine · Westfield, NJNPI 1518487644

Payments from drug & device makers

$4,255in general payments, 2019–2025

Across 215 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$759
  • Novo Nordisk$673
  • GSK$490
  • Lilly USA, LLC$399
  • AstraZeneca$338
  • Pfizer$247
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,255 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$51,958
Medicare patients
279
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol24$38,066
OzempicSemaglutide30$28,299
MounjaroTirzepatide15$15,589
JanuviaSitagliptin Phosphate11$11,582
EliquisApixaban11$10,785
Ezetimibe-SimvastatinEzetimibe/Simvastatin12$2,025
Atorvastatin Calcium112$1,454
Albuterol Sulfate HfaAlbuterol Sulfate30$1,376
Diclofenac Sodium12$1,170
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$948
Rosuvastatin Calcium79$909
Metoprolol Succinate45$692
Levothyroxine Sodium64$594
Amlodipine Besylate85$570
Losartan Potassium55$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$338$38,06624 claims
Novo NordiskOzempic$673$28,29930 claims
Lilly USA, LLCMounjaro$399$15,58915 claims
MerckJanuvia$31$11,58211 claims
PfizerEliquis$247$10,78511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Westfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →